Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Boehringer Ingelheim has made progress with its metabolic dysfunction-associated steatohepatitis (MASH) treatment, linking the Zealand Pharma-partnered candidate to improvements in disease activity ...

What Are Clinical Trials for MASH? Clinical trials for MASH are research studies that evaluate potential new treatments for a form of liver disease called metabolic dysfunction-associated ...

Metabolic dysfunction-associated steatohepatitis (MASH) starts in your liver, but it can have body-wide effects. These effects increase your risk of conditions like heart disease, chronic kidney ...

The MarketWatch News Department was not involved in the creation of this content.-- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment ...

If you have diabetes, you probably know the condition is linked to a greater risk of several health problems, including heart disease, kidney disease, nerve damage, and more. But one risk you may not ...

MASH prevalence is projected to remain under 5% by 2040, with new treatments like resmetirom now available. Diagnostic challenges and underestimation in claims data affect accurate prevalence ...